Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4628 Triple negative breast neuroendocrine carcinoma in older patient: A rare entity

Introduction: Neuroendocrine breast carcinoma is a rare histological form of breast cancer, that represent 0.1% of all breast cancers and is recognised by the World Health Organization as a distinct entity. Characterised by a non-specific clinical and radiological presentation. Therapeutic management is not codified and is usually superimposed on that of classical breast cancer.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: neuroendocrine carcinoma, triple negative breast cancer, platinum-based combination therapy,

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4605 Primary mammary neuroendocrine tumour: A case report and literature review

Introduction: Primary neuroendocrine carcinomas of the breast are rare, accounting for only 2 to 5% of all breast cancers. These tumours have recently been included in the latest WHO classification of breast tumours. The diagnosis can be challenging due to its uncommon presentation and overlap with other breast pathologies.

Conference:

Presenting Author:

Authors: Boudersa A, Kouadri N,

Keywords: primary neuroendocrine, breast cancer,

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,